This Colorectal Cancer Screening market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
The colorectal cancer screening market size has grown strongly in recent years. It will grow from $14.72 billion in 2023 to $15.61 billion in 2024 at a compound annual growth rate (CAGR) of 6.1%. The growth during the historic period can be attributed to the rising incidence of colorectal cancer, increasing government awareness campaigns, an aging population, greater adoption of colonoscopy, and enhanced insurance coverage.
The colorectal cancer screening market size is expected to see strong growth in the next few years. It will grow to $19.83 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The projected growth during the forecast period can be attributed to a shift towards non-invasive screening methods, the increasing availability of home-based screening tests, the rising prevalence of obesity, a growing adoption of value-based healthcare, and the expansion of public-private partnerships. Key trends anticipated during this period include the integration of artificial intelligence (AI) in screening and diagnostics, the expansion of screening guidelines to younger populations, broader utilization of genomic testing for cancer risk assessment, growth in mobile health (mHealth) platforms, and collaborations between pharmaceutical and diagnostic companies.
The increasing aging population is projected to drive the growth of the colorectal cancer screening market in the coming years. An aging population refers to a demographic trend characterized by a rising proportion of elderly individuals (typically those aged 65 and older) relative to the working-age population, often resulting from longer life expectancies and declining birth rates. As life expectancies increase and birth rates decline, the share of older adults in the global population continues to grow. Colorectal cancer screening plays a crucial role in addressing the needs of this expanding aging population by enabling early detection and preventive measures, which are essential for managing the heightened cancer risk among older adults and improving their overall health outcomes. For example, in January 2024, data from the Population Reference Bureau (PRB), a U.S.-based nonprofit research organization, projected that the number of Americans aged 65 and older would rise from 58 million in 2022 to 82 million by 2050, representing a 47% increase. Additionally, their share of the total population is expected to grow from 17% to 23%. Thus, the increasing aging population is a significant driver of the colorectal cancer screening market.
Key players in the colorectal cancer screening market are focusing on developing innovative solutions, such as non-invasive multi-target stool ribonucleic acid (RNA) colorectal cancer screening tests, to provide accessible and effective early detection methods, thereby improving patient outcomes and promoting wider screening participation. Non-invasive multi-target stool RNA colorectal cancer screening tests evaluate RNA markers from stool samples to identify the presence of colorectal cancer or precancerous lesions, offering a non-surgical approach for early detection. For instance, in May 2024, Geneoscopy Inc., a U.S.-based life sciences company, announced that it received U.S. Food and Drug Administration (FDA) approval for ColoSense. This test utilizes RNA biomarkers for a non-invasive, stool-based screening method that demonstrated 93% sensitivity in detecting colorectal cancer and 45% sensitivity for advanced adenomas. Its significance lies in its high accuracy, particularly among younger populations, and its potential to enhance screening rates by providing a less invasive alternative to traditional methods.
In November 2023, Geneoscopy Inc. partnered with Laboratory Corporation (LabCorp), a U.S.-based life science and healthcare company, to broaden access to Geneoscopy’s non-invasive multi-target stool RNA colorectal cancer screening test. This collaboration aims to improve early and sensitive detection of colorectal cancer and precancerous lesions, address health disparities, and increase screening rates by leveraging LabCorp's extensive network of healthcare providers and patients. LabCorp is known for offering colon cancer screening and diagnostic tests.
Major companies operating in the colorectal cancer screening market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Medtronic plc, Siemens Healthineers, FUJIFILM Holdings Corporation, GE HealthCare, Boston Scientific Corporation, Olympus Corporation, Hologic Inc., bioMérieux SA, QuidelOrtho Corporation, Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, Guardant Health Inc., Eiken Chemical Co. Ltd., HemoCue AB, Clinical Genomics Inc., Polymedco LLC, Hemosure Inc., Geneoscopy Inc., Novigenix SA.
North America was the largest region in the colorectal cancer screening market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the colorectal cancer screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the colorectal cancer screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Colorectal cancer screening refers to testing procedures aimed at detecting early signs of colorectal cancer before symptoms manifest. Early detection through screening can identify precancerous polyps or cancer at a more treatable stage, significantly enhancing patient outcomes. Screening is recommended for adults starting at age 45, or earlier for those at higher risk.
The primary types of colorectal cancer screening include stool-based tests, fecal immunochemical tests (FIT), fecal occult blood tests (FOBT), stool deoxyribonucleic acid (DNA) tests, and colonoscopy, among others. Stool-based colorectal cancer screening involves analyzing a stool sample for indicators of cancer-related substances or abnormalities, such as blood or DNA mutations, to identify potential colorectal cancer. These screenings are categorized by age groups, including individuals under 50, those aged 50-64, and those over 65. The end users of these tests encompass hospitals and clinics, clinical laboratories, diagnostic imaging centers, and other healthcare providers.
The colorectal cancer screening market research report is one of a series of new reports that provides colorectal cancer screening market statistics, including colorectal cancer screening industry global market size, regional shares, competitors with a colorectal cancer screening market share, detailed colorectal cancer screening market segments, market trends and opportunities, and any further data you may need to thrive in the colorectal cancer screening industry. This colorectal cancer screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The colorectal cancer screening market includes revenues earned by entities by providing services such as genetic and molecular testing, patient education and awareness programs, and screening result analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The colorectal cancer screening market size has grown strongly in recent years. It will grow from $14.72 billion in 2023 to $15.61 billion in 2024 at a compound annual growth rate (CAGR) of 6.1%. The growth during the historic period can be attributed to the rising incidence of colorectal cancer, increasing government awareness campaigns, an aging population, greater adoption of colonoscopy, and enhanced insurance coverage.
The colorectal cancer screening market size is expected to see strong growth in the next few years. It will grow to $19.83 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The projected growth during the forecast period can be attributed to a shift towards non-invasive screening methods, the increasing availability of home-based screening tests, the rising prevalence of obesity, a growing adoption of value-based healthcare, and the expansion of public-private partnerships. Key trends anticipated during this period include the integration of artificial intelligence (AI) in screening and diagnostics, the expansion of screening guidelines to younger populations, broader utilization of genomic testing for cancer risk assessment, growth in mobile health (mHealth) platforms, and collaborations between pharmaceutical and diagnostic companies.
The increasing aging population is projected to drive the growth of the colorectal cancer screening market in the coming years. An aging population refers to a demographic trend characterized by a rising proportion of elderly individuals (typically those aged 65 and older) relative to the working-age population, often resulting from longer life expectancies and declining birth rates. As life expectancies increase and birth rates decline, the share of older adults in the global population continues to grow. Colorectal cancer screening plays a crucial role in addressing the needs of this expanding aging population by enabling early detection and preventive measures, which are essential for managing the heightened cancer risk among older adults and improving their overall health outcomes. For example, in January 2024, data from the Population Reference Bureau (PRB), a U.S.-based nonprofit research organization, projected that the number of Americans aged 65 and older would rise from 58 million in 2022 to 82 million by 2050, representing a 47% increase. Additionally, their share of the total population is expected to grow from 17% to 23%. Thus, the increasing aging population is a significant driver of the colorectal cancer screening market.
Key players in the colorectal cancer screening market are focusing on developing innovative solutions, such as non-invasive multi-target stool ribonucleic acid (RNA) colorectal cancer screening tests, to provide accessible and effective early detection methods, thereby improving patient outcomes and promoting wider screening participation. Non-invasive multi-target stool RNA colorectal cancer screening tests evaluate RNA markers from stool samples to identify the presence of colorectal cancer or precancerous lesions, offering a non-surgical approach for early detection. For instance, in May 2024, Geneoscopy Inc., a U.S.-based life sciences company, announced that it received U.S. Food and Drug Administration (FDA) approval for ColoSense. This test utilizes RNA biomarkers for a non-invasive, stool-based screening method that demonstrated 93% sensitivity in detecting colorectal cancer and 45% sensitivity for advanced adenomas. Its significance lies in its high accuracy, particularly among younger populations, and its potential to enhance screening rates by providing a less invasive alternative to traditional methods.
In November 2023, Geneoscopy Inc. partnered with Laboratory Corporation (LabCorp), a U.S.-based life science and healthcare company, to broaden access to Geneoscopy’s non-invasive multi-target stool RNA colorectal cancer screening test. This collaboration aims to improve early and sensitive detection of colorectal cancer and precancerous lesions, address health disparities, and increase screening rates by leveraging LabCorp's extensive network of healthcare providers and patients. LabCorp is known for offering colon cancer screening and diagnostic tests.
Major companies operating in the colorectal cancer screening market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Medtronic plc, Siemens Healthineers, FUJIFILM Holdings Corporation, GE HealthCare, Boston Scientific Corporation, Olympus Corporation, Hologic Inc., bioMérieux SA, QuidelOrtho Corporation, Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, Guardant Health Inc., Eiken Chemical Co. Ltd., HemoCue AB, Clinical Genomics Inc., Polymedco LLC, Hemosure Inc., Geneoscopy Inc., Novigenix SA.
North America was the largest region in the colorectal cancer screening market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the colorectal cancer screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the colorectal cancer screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Colorectal cancer screening refers to testing procedures aimed at detecting early signs of colorectal cancer before symptoms manifest. Early detection through screening can identify precancerous polyps or cancer at a more treatable stage, significantly enhancing patient outcomes. Screening is recommended for adults starting at age 45, or earlier for those at higher risk.
The primary types of colorectal cancer screening include stool-based tests, fecal immunochemical tests (FIT), fecal occult blood tests (FOBT), stool deoxyribonucleic acid (DNA) tests, and colonoscopy, among others. Stool-based colorectal cancer screening involves analyzing a stool sample for indicators of cancer-related substances or abnormalities, such as blood or DNA mutations, to identify potential colorectal cancer. These screenings are categorized by age groups, including individuals under 50, those aged 50-64, and those over 65. The end users of these tests encompass hospitals and clinics, clinical laboratories, diagnostic imaging centers, and other healthcare providers.
The colorectal cancer screening market research report is one of a series of new reports that provides colorectal cancer screening market statistics, including colorectal cancer screening industry global market size, regional shares, competitors with a colorectal cancer screening market share, detailed colorectal cancer screening market segments, market trends and opportunities, and any further data you may need to thrive in the colorectal cancer screening industry. This colorectal cancer screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The colorectal cancer screening market includes revenues earned by entities by providing services such as genetic and molecular testing, patient education and awareness programs, and screening result analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Colorectal Cancer Screening Market Characteristics3. Colorectal Cancer Screening Market Trends and Strategies32. Global Colorectal Cancer Screening Market Competitive Benchmarking33. Global Colorectal Cancer Screening Market Competitive Dashboard34. Key Mergers and Acquisitions in the Colorectal Cancer Screening Market
4. Colorectal Cancer Screening Market - Macro Economic Scenario
5. Global Colorectal Cancer Screening Market Size and Growth
6. Colorectal Cancer Screening Market Segmentation
7. Colorectal Cancer Screening Market Regional and Country Analysis
8. Asia-Pacific Colorectal Cancer Screening Market
9. China Colorectal Cancer Screening Market
10. India Colorectal Cancer Screening Market
11. Japan Colorectal Cancer Screening Market
12. Australia Colorectal Cancer Screening Market
13. Indonesia Colorectal Cancer Screening Market
14. South Korea Colorectal Cancer Screening Market
15. Western Europe Colorectal Cancer Screening Market
16. UK Colorectal Cancer Screening Market
17. Germany Colorectal Cancer Screening Market
18. France Colorectal Cancer Screening Market
19. Italy Colorectal Cancer Screening Market
20. Spain Colorectal Cancer Screening Market
21. Eastern Europe Colorectal Cancer Screening Market
22. Russia Colorectal Cancer Screening Market
23. North America Colorectal Cancer Screening Market
24. USA Colorectal Cancer Screening Market
25. Canada Colorectal Cancer Screening Market
26. South America Colorectal Cancer Screening Market
27. Brazil Colorectal Cancer Screening Market
28. Middle East Colorectal Cancer Screening Market
29. Africa Colorectal Cancer Screening Market
30. Colorectal Cancer Screening Market Competitive Landscape and Company Profiles
31. Colorectal Cancer Screening Market Other Major and Innovative Companies
35. Colorectal Cancer Screening Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Colorectal Cancer Screening Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on colorectal cancer screening market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for colorectal cancer screening? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The colorectal cancer screening market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Stool-Based; Fecal Immunochemical Test (FIT); Fecal Occult Blood Test (FOBT); Stool Deoxyribonucleic Acid (DNA) Test; Colonoscopy; Other Types2) By Age Group: Below 50 Years; 50-64 Years; Above 65 Years
3) By End User: Hospitals and Clinics; Clinical Laboratories; Diagnostic Imaging Centers; Other End-Users
Key Companies Mentioned: F. Hoffmann-La Roche AG; Thermo Fisher Scientific Inc.; Abbott Laboratories; Medtronic plc; Siemens Healthineers
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies profiled in this Colorectal Cancer Screening market report include:- F. Hoffmann-La Roche AG
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Medtronic plc
- Siemens Healthineers
- FUJIFILM Holdings Corporation
- GE HealthCare
- Boston Scientific Corporation
- Olympus Corporation
- Hologic Inc.
- bioMérieux SA
- QuidelOrtho Corporation
- Sysmex Corporation
- QIAGEN N.V.
- Exact Sciences Corporation
- Guardant Health Inc.
- Eiken Chemical Co. Ltd.
- HemoCue AB
- Clinical Genomics Inc.
- Polymedco LLC
- Hemosure Inc.
- Geneoscopy Inc.
- Novigenix SA
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | November 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 15.61 Billion |
| Forecasted Market Value ( USD | $ 19.83 Billion |
| Compound Annual Growth Rate | 6.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 24 |
